Ocular Therapeutix, Inc. will make slides available under the Investors section of its corporate website. The slides will detail results from the SOL-1 Phase 3 superiority clinical trial of AXPAXLI (also known as OTX-TKI). The trial is for the treatment of wet age-related macular degeneration. The presentation will occur at the 49th Macula Society Annual Meeting.